NASDAQ:HOTHHoth Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Hoth Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.65 -0.29 (-9.86 %) (As of 08/12/2020 04:00 PM ET) Add Compare Share Today's Range$2.64Now: $2.65▼$2.8950-Day Range$2.50MA: $2.71▼$3.1552-Week Range$2.31Now: $2.65▼$7.25Volume13,904 shsAverage Volume509,933 shsMarket Capitalization$35.56 millionP/E RatioN/ADividend YieldN/ABeta0.98 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Hoth Therapeutics, Inc., a development stage biopharmaceutical company, focuses on developing targeted therapeutics for atopic dermatitis. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company was incorporated in 2017 and is based in New York.Read More Beat the Market (BTM) Rank™ 3.0 Analyst's Opinion Consensus RatingHoth Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Hoth Therapeutics has a potential upside of 270.4% from its current price of $2.70.Amount of Analyst CoverageHoth Therapeutics has received no research coverage in the past 90 days. Previous Next 2.3 Community Rank Outperform VotesHoth Therapeutics has received 55 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHoth Therapeutics has received 64 “underperform” votes. (Add your “underperform” vote.)Community SentimentHoth Therapeutics has received 53.78% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Hoth Therapeutics and other stocks. Vote “Outperform” if you believe HOTH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HOTH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHoth Therapeutics does not currently pay a dividend.Dividend GrowthHoth Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hoth Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $500,000.00 in company stock.Percentage Held by InsidersOnly 17.27% of the stock of Hoth Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 0.24% of the stock of Hoth Therapeutics is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioHoth Therapeutics has a P/B Ratio of 11.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.06 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HOTH Previous Symbol CUSIPN/A CIKN/A Webwww.hoththerapeutics.com Phone646-756-2997Debt Debt-to-Equity RatioN/A Current Ratio9.36 Quick Ratio9.36Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.24 per share Price / Book11.04Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-7,700,000.00 Net MarginsN/A Return on Equity-221.49% Return on Assets-205.42%Miscellaneous Employees2 Outstanding Shares13,420,000Market Cap$35.56 million Next Earnings Date8/12/2020 (Estimated) OptionableNot Optionable $2.65 -0.29 (-9.86 %) (As of 08/12/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive HOTH News and Ratings via Email Sign-up to receive the latest news and ratings for HOTH and its competitors with MarketBeat's FREE daily newsletter. Hoth Therapeutics (NASDAQ:HOTH) Frequently Asked Questions How has Hoth Therapeutics' stock price been impacted by COVID-19 (Coronavirus)? Hoth Therapeutics' stock was trading at $3.84 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HOTH shares have decreased by 31.0% and is now trading at $2.65. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Hoth Therapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Hoth Therapeutics. When is Hoth Therapeutics' next earnings date? Hoth Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Hoth Therapeutics. How were Hoth Therapeutics' earnings last quarter? Hoth Therapeutics Inc (NASDAQ:HOTH) posted its earnings results on Wednesday, May, 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01. View Hoth Therapeutics' earnings history. What price target have analysts set for HOTH? 1 brokerages have issued 1 year price objectives for Hoth Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Hoth Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 277.4% from the stock's current price. View analysts' price targets for Hoth Therapeutics. Has Hoth Therapeutics been receiving favorable news coverage? News stories about HOTH stock have been trending negative on Wednesday, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hoth Therapeutics earned a news impact score of -2.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View the latest news about Hoth Therapeutics. Are investors shorting Hoth Therapeutics? Hoth Therapeutics saw a increase in short interest in February. As of February 15th, there was short interest totaling 25,500 shares, an increase of 99.2% from the January 31st total of 12,800 shares. Based on an average trading volume of 47,200 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.6% of the shares of the stock are short sold. View Hoth Therapeutics' Short Interest. Who are some of Hoth Therapeutics' key competitors? Some companies that are related to Hoth Therapeutics include Galectin Therapeutics (GALT), Evofem Biosciences (EVFM), Minerva Neurosciences (NERV), Eton Pharmaceuticals (ETON), CELYAD SA/ADR (CYAD), Genprex (GNPX), Adamas Pharmaceuticals (ADMS), ESSA Pharma (EPIX), Mustang Bio (MBIO), Evoke Pharma (EVOK), OASMIA PHARMACE/ADR (OASM), Obseva (OBSV), Tonix Pharmaceuticals (TNXP), Evolus (EOLS) and Axovant Gene Therapies (AXGT). View all competitors. What other stocks do shareholders of Hoth Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Citius Pharmaceuticals (CTXR), Fulcrum Therapeutics (FULC), AIM ImmunoTech (AIM), Aytu Bioscience (AYTU), Gilead Sciences (GILD), Heat Biologics (HTBX), Opko Health (OPK), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV) and Xeris Pharmaceuticals (XERS). Who are Hoth Therapeutics' key executives? Hoth Therapeutics' management team includes the following people: Mr. Robb Knie, Pres, CEO & Director (Age 50)Mr. David S. Briones, Chief Financial Officer (Age 43)Ms. Jane H. Behrmann, VP of Operations (Age 34) When did Hoth Therapeutics IPO? (HOTH) raised $8 million in an initial public offering on Friday, February 15th 2019. The company issued 1,300,000 shares at a price of $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO. What is Hoth Therapeutics' stock symbol? Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH." Who are Hoth Therapeutics' major shareholders? Hoth Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.17%), Magnus Financial Group LLC (0.10%) and Game Plan Financial Advisors LLC (0.08%). View institutional ownership trends for Hoth Therapeutics. Which institutional investors are buying Hoth Therapeutics stock? HOTH stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc., Magnus Financial Group LLC, and Game Plan Financial Advisors LLC. View insider buying and selling activity for Hoth Therapeutics. How do I buy shares of Hoth Therapeutics? Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Hoth Therapeutics' stock price today? One share of HOTH stock can currently be purchased for approximately $2.65. How big of a company is Hoth Therapeutics? Hoth Therapeutics has a market capitalization of $35.56 million. Hoth Therapeutics employs 2 workers across the globe. What is Hoth Therapeutics' official website? The official website for Hoth Therapeutics is www.hoththerapeutics.com. How can I contact Hoth Therapeutics? Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
